{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:31:39Z","timestamp":1782891099697,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81788101"],"award-info":[{"award-number":["81788101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences"},{"name":"the National Key Research and Development Plan of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Discov"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participating centers. Multivariate logistic regression was conducted in patients with comorbid hypertension to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of ACEI, ARB, calcium-channel blockers (CCB), beta-blockers (BB), and thiazide diuretics. The clinical outcome, dyspnea, and fatigue were significantly improved in patients, especially elderly patients who were older than 65 years, who took ARB drugs prior to hospitalization compared to patients who took no drugs. The reduction of disease severity of elderly COVID-19 patients was associated with CCB and ACEI users. Clinical indices, including CRP, lymphocyte count, procalcitonin D dimer, and hemoglobin, were significantly improved in elderly ARB users. In addition, the clinical outcomes were statistically significantly improved in patients who took antihypertension drugs ARB, BB, and CCB after statistical adjustment by all ages, gender, baseline of blood pressures, and coexisting medical conditions. Our data indicate that hypertension drugs ARB, ACEI, CCB, and BB might be beneficial for COVID-19 patients.<\/jats:p>","DOI":"10.1038\/s41421-020-00221-6","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T21:02:41Z","timestamp":1604005361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients"],"prefix":"10.1038","volume":"6","author":[{"given":"Feifei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuxiu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-615X","authenticated-orcid":false,"given":"George F.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-6685","authenticated-orcid":false,"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"221_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF-W Chan","year":"2020","unstructured":"Chan, J. F.-W. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514\u2013523 (2020).","journal-title":"Lancet"},{"key":"221_CR2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"221_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/jmv.25674","volume":"92","author":"N Zhang","year":"2020","unstructured":"Zhang, N. et al. Recent advances in the detection of respiratory virus infection in humans. J. Med. Virol. 92, 408\u2013417 (2020).","journal-title":"J. Med. Virol."},{"key":"221_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui, D. S. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health\u2014the latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 91, 264\u2013266 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"221_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470\u2013473 (2020).","journal-title":"Lancet"},{"key":"221_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"221_CR7","unstructured":"Liu, Y. et al. Elevated levels of plasma cytokines in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection reflect viral load and lung injury. Natl Sci. Rev. (2020)."},{"key":"221_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 63, 364\u2013374 (2020).","journal-title":"Sci. China Life Sci."},{"key":"221_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005).","journal-title":"Nat. Med."},{"key":"221_CR10","first-page":"420","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Resp. Med. 8, 420\u2013422 (2020).","journal-title":"Resp. Med."},{"key":"221_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4595","volume":"5","author":"F Huang","year":"2014","unstructured":"Huang, F. et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat. Commun. 5, 3595 (2014).","journal-title":"Nat. Commun."},{"key":"221_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005).","journal-title":"Nature"},{"key":"221_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4594","volume":"5","author":"Z Zou","year":"2014","unstructured":"Zou, Z. et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat. Commun. 5, 3594 (2014).","journal-title":"Nat. Commun."},{"key":"221_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","volume":"98","author":"SJ Forrester","year":"2018","unstructured":"Forrester, S. J. et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol. Rev. 98, 1627\u20131738 (2018).","journal-title":"Physiol. Rev."},{"key":"221_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188975","volume":"12","author":"YC Lin","year":"2017","unstructured":"Lin, Y. C. et al. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis. PLoS ONE 12, e0188975 (2017).","journal-title":"PLoS ONE"},{"key":"221_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11427-015-4814-7","volume":"58","author":"YW Yan","year":"2015","unstructured":"Yan, Y. W. et al. Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. Sci. China Life Sci. 58, 208\u2013211 (2015).","journal-title":"Sci. China Life Sci."},{"key":"221_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0140-6736(05)60114-6","volume":"352","author":"K Sekizawa","year":"1998","unstructured":"Sekizawa, K., Matsui, T., Nakagawa, T., Nakayama, K. & Sasaki, H. ACE inhibitors and pneumonia. Lancet 352, 1069 (1998).","journal-title":"Lancet"},{"key":"221_CR18","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(05)60437-0","volume":"352","author":"T Arai","year":"1998","unstructured":"Arai, T., Yasuda, Y., Toshima, S., Yoshimi, N. & Kashiki, Y. ACE inhibitors and pneumonia in elderly people. Lancet 352, 1937\u20131938 (1998).","journal-title":"Lancet"},{"key":"221_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/PHM.0b013e3181909b73","volume":"88","author":"C Marciniak","year":"2009","unstructured":"Marciniak, C. et al. Examination of selected clinical factors and medication use as risk factors for pneumonia during stroke rehabilitation: a case-control study. Am. J. Phys. Med. Rehabil. 88, 30\u201338 (2009).","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"221_CR20","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.2020.8946","volume":"323","author":"AB Patel","year":"2020","unstructured":"Patel, A. B. & Verma, A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA 323, 1769\u20131770 (2020).","journal-title":"JAMA"},{"key":"221_CR21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"OV Muthiah Vaduganathan","year":"2020","unstructured":"Muthiah Vaduganathan, O. V. et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med. 382, 1653\u20131659 (2020).","journal-title":"N. Engl. J. Med."},{"key":"221_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/cr.2008.15","volume":"18","author":"HL Wang","year":"2008","unstructured":"Wang, H. L. et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 18, 290\u2013301 (2008).","journal-title":"Cell Res."},{"key":"221_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12989-015-0080-x","volume":"12","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice. Part Fibre Toxicol. 12, 4 (2015).","journal-title":"Part Fibre Toxicol."},{"key":"221_CR24","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/cid\/cis733","volume":"55","author":"EM Mortensen","year":"2012","unstructured":"Mortensen, E. M. et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin. Infect. Dis. 55, 1466\u20131473 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"221_CR25","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126, 1671\u20131681 (2020).","journal-title":"Circ. Res."},{"key":"221_CR26","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds, H. R. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N. Engl. J. Med. 382, 2441\u20132448 (2020).","journal-title":"N. Engl. J. Med."},{"key":"221_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"GX Juan Menga","year":"2020","unstructured":"Juan Menga, G. X. & Juanjuan, Z. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microbes Infect. 9, 757\u2013760 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"221_CR28","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","volume":"41","author":"IE Sama","year":"2020","unstructured":"Sama, I. E. et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur. Heart J. 41, 1810\u20131817 (2020).","journal-title":"Eur. Heart J."},{"key":"221_CR29","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia, G., Rea, F., Ludergnani, M., Apolone, G. & Corrao, G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N. Engl. J. Med. 382, 2431\u20132440 (2020).","journal-title":"N. Engl. J. Med."},{"key":"221_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","volume":"92","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 92, 791\u2013796 (2020).","journal-title":"J. Med. Virol."},{"key":"221_CR31","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1515\/cclm-2020-0188","volume":"58","author":"H Han","year":"2020","unstructured":"Han, H. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. 58, 1116\u20131120 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"221_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li, J., Wang, X., Chen, J., Zhang, H. & Deng, A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 5, 825\u2013830 (2020).","journal-title":"JAMA Cardiol."},{"key":"221_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta, N. et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 1020\u20131026 (2020).","journal-title":"JAMA Cardiol."},{"key":"221_CR34","doi-asserted-by":"publisher","unstructured":"Hu, J. et al. COVID-19 patients with hypertension have more severity condition, and ACEI\/ARB treatment have no infulence on the clinical severity and outcome. J. Infect. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.056 (2020).","DOI":"10.1016\/j.jinf.2020.05.056"},{"key":"221_CR35","doi-asserted-by":"publisher","unstructured":"Jung, S. Y., Choi, J. C., You, S. H. & Kim, W. Y. Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa624 (2020).","DOI":"10.1093\/cid\/ciaa624"},{"key":"221_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.therap.2020.05.005","volume":"75","author":"F Montastruc","year":"2020","unstructured":"Montastruc, F. et al. Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to intensive care unit in South of France. Therapie 75, 381\u2013384 (2020).","journal-title":"Therapie"},{"key":"221_CR37","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","volume":"159","author":"ND Tan","year":"2020","unstructured":"Tan, N. D. et al. Associations between angiotensin converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19. Gastroenterology 159, 1170\u20131172 (2020).","journal-title":"Gastroenterology"},{"key":"221_CR38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/dc20-0660","volume":"43","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43, 1399\u20131407 (2020).","journal-title":"Diabetes Care"},{"key":"221_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/10641963.2020.1764018","volume":"42","author":"X Zhou","year":"2020","unstructured":"Zhou, X., Zhu, J. & Xu, T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin. Exp. Hypertens. 42, 656\u2013660 (2020).","journal-title":"Clin. Exp. Hypertens."},{"key":"221_CR40","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Res. 126, 1671\u20131681 (2020).","journal-title":"Circulation Res."},{"key":"221_CR41","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","volume":"201","author":"Y Feng","year":"2020","unstructured":"Feng, Y. et al. COVID-19 with different severities: a multicenter study of clinical features. Am. J. Resp. Crit. Care Med. 201, 1380\u20131388 (2020).","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"221_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosbol","year":"2020","unstructured":"Fosbol, E. L. et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324, 168\u2013177 (2020).","journal-title":"JAMA"},{"key":"221_CR43","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","volume":"222","author":"KW Lam","year":"2020","unstructured":"Lam, K. W. et al. Continued in-hospital ACE inhibitor and ARB use in hypertensive COVID-19 patients is associated with positive clinical outcomes. J. Infect. Dis. 222, 1256\u20131264 (2020).","journal-title":"J. Infect. Dis."},{"key":"221_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng, J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microbes Infect. 9, 757\u2013760 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"221_CR45","doi-asserted-by":"publisher","unstructured":"Oussalah, A. et al. Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the North East of France. Clin. infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa677 (2020).","DOI":"10.1093\/cid\/ciaa677"},{"key":"221_CR46","first-page":"E004","volume":"48","author":"YD Peng","year":"2020","unstructured":"Peng, Y. D. et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing. Za Zhi 48, E004 (2020).","journal-title":"Zhonghua Xin Xue Guan Bing. Za Zhi"},{"key":"221_CR47","first-page":"e15","volume":"76","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension 76, e15\u2013e17 (2020).","journal-title":"Hypertension"},{"key":"221_CR48","doi-asserted-by":"crossref","unstructured":"Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D. & Patel, A. N. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. 382, e102 (2020). Retracted","DOI":"10.1056\/NEJMoa2007621"},{"key":"221_CR49","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","volume":"385","author":"SC Palmer","year":"2015","unstructured":"Palmer, S. C. et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385, 2047\u20132056 (2015).","journal-title":"Lancet"},{"key":"221_CR50","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0886022X.2014.900425","volume":"36","author":"P Dhakarwal","year":"2014","unstructured":"Dhakarwal, P., Agrawal, V., Kumar, A., Goli, K. M. & Agrawal, V. Update on role of direct renin inhibitor in diabetic kidney disease. Ren. Fail. 36, 963\u2013969 (2014).","journal-title":"Ren. Fail."},{"key":"221_CR51","doi-asserted-by":"publisher","first-page":"104832","DOI":"10.1016\/j.phrs.2020.104832","volume":"156","author":"JM Saavedra","year":"2020","unstructured":"Saavedra, J. M. Angiotensin receptor blockers and COVID-19. Pharm. Res. 156, 104832 (2020).","journal-title":"Pharm. Res."},{"key":"221_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. 81, 537\u2013540 (2020).","journal-title":"Drug Dev. Res."},{"key":"221_CR53","unstructured":"W. H. O. Laboratory Testing for 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases: Interim Guidance (World Health Organization, 2020)."},{"key":"221_CR54","first-page":"10","volume":"48","author":"Bureau of Disease P, C. N., National Center for Cardiovascular D, et al.","year":"2019","unstructured":"Bureau of Disease P, C. N., National Center for Cardiovascular D, et al. [National guideline for hypertension management in China (2019)]. Zhonghua Xin Xue Guan Bing. Za Zhi 48, 10\u201346 (2019).","journal-title":"Zhonghua Xin Xue Guan Bing. Za Zhi"},{"key":"221_CR55","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"SE RE","year":"2018","unstructured":"RE, S. E., Tsioufis, C., Aboyans, V. & Desormais, I. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104 (2018).","journal-title":"Eur. Heart J."}],"container-title":["Cell Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41421-020-00221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41421-020-00221-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41421-020-00221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:13:25Z","timestamp":1670256805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41421-020-00221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1038\/s41421-020-00221-6","relation":{},"ISSN":["2056-5968"],"issn-type":[{"value":"2056-5968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"77"}}